Advanced search×

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

M E Trudeau, M J Clemons, L Provencher, L Panasci, L Yelle, D Rayson, J Latreille, T Vandenberg, R Goel, L Zibdawi, Y Rahim, and J-F Pouliot

J Clin Oncol 27(35):5906-5910 (2009) PMID 19858391

Anthracyclines are a component of breast cancer chemotherapy regimens in both adjuvant and metastatic settings. Anthracycline rechallenge for metastatic disease, for those previously exposed to adjuvant anthracyclines, may not be considered because of concerns about efficacy, tolerability, and cumulative cardiotoxicity.

DOI: 10.1200/JCO.2009.22.7504
Version: za2963e q8za1 q8zb6 q8zc7 q8zd0 q8zee q8zf9 q8zg1

Similar articles you may find interesting…

  1. How to restore public trust about breast cancer screening? An opportunity to reinforce the need for further advances in science and technolo...
    Shahla Masood

    Breast J 16(1):1-3 (2010) PMID 20465597

    View PDF
  2. Providing Protocol Information for Journal of Clinical Oncology Readers: What Practicing Clinicians Need to Know
    D G Haller and S A Cannistra

    J Clin Oncol 29(9):1091 (2011) PMID 21321293